BMS Reports Result of Opdivo (nivolumab) + Yervoy (ipilimumab) + CT in P-III CheckMate-9LA Study as 1L Therapy for Lung Cancer

BMS’s Triple Regimen Receives European Commission Approval for Relapse and Refractory Multiple MyelomaBMS’s Triple Regimen Receives European Commission Approval for Relapse and Refractory Multiple Myeloma

Shots:

  • The P-III CheckMate -9LA study involve assessing of Opdivo (360mg q3w) + Yervoy (1mg/kg q6w) combined with CT (two cycles) vs CT as monothx. (up to four cycles followed by optional pemetrexed maintenance therapy if eligible) as a 1L treatment in patients with advanced NSCLC regardless of PD-L1 expression and histology
  • The P-III CheckMate -9LA study resulted in meeting 1EPs of superior overall survival (OS) at a pre-specified interim analysis. 2EPs includes PFS, ORR and efficacy measures according to biomarker
  • Opdivo is a PD-1 immune check inhibitor harnessing the body’s own immune system to restore anti-tumor immune response while the Opdivo and Yervoy dual regimen was the first Immuno-Oncology combination to receive approval for metastatic melanoma and is approved in 50+ countries including the US & EU

Click here to­ read full press release/ article | Ref: BMS | Image: Pharmaceutical Technology